PE-CAV
_________________________________________________________________
  cisplatin....... 60 mg/sqm IV after 500 ml 5% dextrose in saline 
                   on days 1 and 22.
  etoposide....... 120 mg/sqm IV on days 4, 6, 8, 25, 27 and 29.
  cytoxan......... 1,000 mg/sqm IV on days 42, 63, 84 and 105.
  adriamycin...... 40 mg/sqm IV on days 42, 63, 84 and 105.
  vincristine..... 1.4 mg/sqm IV on days 42, 63, 84, 105.
  FREQUENCY....... Repeat cycle every 126 days for 18 months or 
                   relapse.


  reference...
    Sierocki JS.  Hilaris BS.  Hopfan S.  Martini N.  Barton D. 
    Golbey RB.  Wittes RE. cis-Dichlorodiammineplatinum(II) and 
    VP-16-213: an active induction regimen for small cell 
    carcinoma of the lung. Cancer Treatment Reports.  
    63(9-10):1593-7, 1979 Sep-Oct. 
  abstract...
    Thirty-eight patients with small cell carcinoma and no prior 
    therapy were treated with a combination chemotherapy program 
    including 60 mg/m2 of cis-dichlorodiammineplatinum(II) 
    (cis-platinum) iv on Days 1 and 22 and 120 mg/m2 of VP-16-213 
    iv on Days 4, 6, 8, 25, 27, and 29. This was followed by 1000 
    mg/m2 of cyclophosphamide, 40 mg/m2 of Adriamycin, and 1.4 
    mg/m2 of vincristine, all given iv on Days 42, 63, 84, and 
    105. The program was then recycled, with cis-platinum and 
    VP-16-213 beginning on Day 126 and the regimen repeated as 
    above. All patients received prophylactic whole-brain 
    radiation (usually at a dose of 3000 rads in ten fractions) 
    between Days 42 and 63. The projected duration of treatment is 
    18 months in the absence of relapse. In 21 patients with 
    limited disease, the complete response rate was 52% 
    (5.75+--15.25+ months) and the partial remission rate was 48% 
    (2.25--10.5 months). The extensive-disease group showed a 
    complete remission rate of 41% (4.75--11+ months) and a 
    partial remission rate of 47% (3.75--11.5+ months). Response 
    to therapy with cis-platinum and VP-16-213 was very rapid and 
    invariably maximal by the end of the 6-week induction period. 
    Survival for the limited-disease group appears encouraging but 
    followup time is insufficient. Toxicity included nausea and 
    vomiting, myelosuppression, alopecia, and renal insufficiency 
    which was dose-limiting in two patients. The cis-platinum and 
    VP-16-213 combination is clearly an active induction regimen 
    in small cell carcinoma of the lung, but whether it will play 
    a role in increasing long-term survival rates remains to be 
    seen.